## Max Seidensticker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9596274/publications.pdf

Version: 2024-02-01

201575 175177 3,109 122 27 52 citations h-index g-index papers 126 126 126 3357 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 2009, 30, 589-597.	1.3	296
2	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 1164-1174.	1.8	249
3	Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. European Heart Journal, 2010, 31, 489-501.	1.0	201
4	Matched-Pair Comparison of Radioembolization Plus Best Supportive Care Versus Best Supportive Care Alone for Chemotherapy Refractory Liver-Dominant Colorectal Metastases. CardioVascular and Interventional Radiology, 2012, 35, 1066-1073.	0.9	137
5	Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology, 2014, 59, 1864-1873.	3.6	133
6	FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). Journal of Clinical Oncology, 2019, 37, 3401-3411.	0.8	132
7	Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 479-485.	0.4	124
8	Computed Tomography–Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. International Journal of Radiation Oncology Biology Physics, 2010, 78, 172-179.	0.4	111
9	Liver Malignancies: CT-Guided Interstitial Brachytherapy in Patients with Unfavorable Lesions for Thermal Ablation. Journal of Vascular and Interventional Radiology, 2004, 15, 1279-1286.	0.2	110
10	Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach. CardioVascular and Interventional Radiology, 2012, 35, 1109-1118.	0.9	74
11	In vivo assessment of the tolerance dose of small liver volumes after single-fraction HDR irradiation. International Journal of Radiation Oncology Biology Physics, 2005, 62, 776-784.	0.4	59
12	Tracking Long-Term Survival of Intramyocardially Delivered Human Adipose Tissue-Derived Stem Cells Using Bioluminescence Imaging. Molecular Imaging and Biology, 2011, 13, 633-645.	1.3	57
13	Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study. Radiotherapy and Oncology, 2011, 100, 314-319.	0.3	55
14	Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. Journal of Translational Medicine, 2019, 17, 328.	1.8	51
15	Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiation Oncology, 2011, 6, 40.	1.2	49
16	Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity. PLoS ONE, 2014, 9, e112731.	1.1	46
17	Estimation of return-to-sports-time for athletes with stress fracture $\hat{a} \in \hat{a}$ an approach combining risk level of fracture site with severity based on imaging. BMC Musculoskeletal Disorders, 2012, 13, 139.	0.8	40
18	Hybrid SPECT/CT for the assessment of a painful hip after uncemented total hip arthroplasty. BMC Medical Imaging, 2015, 15, 18.	1.4	40

#	Article	IF	Citations
19	Radiotherapy of Liver Metastases. Strahlentherapie Und Onkologie, 2008, 184, 256-261.	1.0	39
20	Human Tissue-Resident Stem Cells Combined with Hyaluronic Acid Gel Provide Fibrovascular-Integrated Soft-Tissue Augmentation in a Murine Photoaged Skin Model. Plastic and Reconstructive Surgery, 2010, 125, 63-73.	0.7	38
21	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	1.8	37
22	Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy. Strahlentherapie Und Onkologie, 2016, 192, 288-296.	1.0	34
23	Safety of Repeated Radioembolizations in Patients with Advanced Primary and Secondary Liver Tumors and Progressive Disease After First Selective Internal Radiotherapy. Journal of Nuclear Medicine, 2014, 55, 360-366.	2.8	33
24	Evaluation of proton and photon dose distributions recalculated on 2D and 3D Unet-generated pseudoCTs from T1-weighted MR head scans. Acta Oncol $\tilde{A}^3$ gica, 2019, 58, 1429-1434.	0.8	33
25	Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiation Oncology, 2010, 5, 44.	1.2	31
26	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial. CardioVascular and Interventional Radiology, 2019, 42, 239-249.	0.9	31
27	Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer, 2016, 16, 509.	1.1	30
28	CT-Guided Brachytherapy (CTGB) versus Interstitial Laser Ablation (ILT) of Colorectal Liver Metastases. Strahlentherapie Und Onkologie, 2008, 184, 302-306.	1.0	27
29	Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterology Research and Practice, 2016, 2016, 1-13.	0.7	27
30	Cytokines and 90Y-Radioembolization: Relation to Liver Function and Overall Survival. CardioVascular and Interventional Radiology, 2017, 40, 1185-1195.	0.9	27
31	Radiation-Induced Liver Damage: Correlation of Histopathology with Hepatobiliary Magnetic Resonance Imaging, a Feasibility Study. CardioVascular and Interventional Radiology, 2015, 38, 213-221.	0.9	25
32	Integration of chemoembolization and radioembolization into multimodal treatment of cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 319-332.	1.0	24
33	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Reports, 2020, 2, 100173.	2.6	24
34	Multispectral optoacoustic tomography of peripheral arterial disease based on muscle hemoglobin gradientsâ€"a pilot clinical study. Annals of Translational Medicine, 2021, 9, 36-36.	0.7	23
35	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 1387-1396.	1.8	22
36	The Effect of Biochemical Remission on Bone Metabolism in Cushing's Syndrome: A 2â€Year Followâ€Up Study. Journal of Bone and Mineral Research, 2020, 35, 1711-1717.	3.1	20

3

#	Article	IF	CITATIONS
37	lmage-Guided Interstitial High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma. Digestive Diseases, 2009, 27, 170-174.	0.8	19
38	Wound Microenvironment Sequesters Adipose-Derived Stem Cells in a Murine Model of Reconstructive Surgery in the Setting of Concurrent Distant Malignancy. Plastic and Reconstructive Surgery, 2011, 127, 1467-1477.	0.7	19
39	Prophylactic Embolization of the Cystic Artery Prior to Radioembolization of Liver Malignancies—An Evaluation of Necessity. CardioVascular and Interventional Radiology, 2015, 38, 678-684.	0.9	19
40	Phase II Feasibility Study on the Combination of Two Different Regional Treatment Approaches in Patients with Colorectal "Liver-Only―Metastases: Hepatic Interstitial Brachytherapy Plus Regional Chemotherapy. CardioVascular and Interventional Radiology, 2009, 32, 937-945.	0.9	18
41	Hepatocellular Carcinoma and Liver Cirrhosis: Assessment of the Liver Function after Yttrium-90 Radioembolization with Resin Microspheres or after CT-Guided High-Dose-Rate Brachytherapy. Digestive Diseases, 2009, 27, 189-199.	0.8	18
42	Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival. BMC Cancer, 2018, 18, 882.	1.1	18
43	Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2022, 126, 211-218.	2.9	18
44	Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer, 2020, 9, 771-786.	4.2	17
45	In VivoAssessment of Dose Volume and Dose Gradient Effects on the Tolerance Dose of Small Liver Volumes after Single-Fraction High-Dose-Rate192Ir Irradiation. Radiation Research, 2009, 172, 598-606.	0.7	16
46	Haemorrhagic Complications and Symptomatic Venous Thromboembolism in Interventional Tumour Ablations: The Impact of Peri-interventional Thrombosis Prophylaxis. CardioVascular and Interventional Radiology, 2016, 39, 1716-1721.	0.9	16
47	Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases. Radiation Oncology, 2010, 5, 24.	1.2	15
48	3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates. Physica Medica, 2020, 80, 317-326.	0.4	15
49	Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. Cancers, 2021, 13, 1507.	1.7	15
50	Percutaneous Sclerotherapy of Venous Malformations of the Hand: A Multicenter Analysis. CardioVascular and Interventional Radiology, 2021, 44, 1543-1550.	0.9	14
51	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncology, 2022, 18, 1423-1435.	1.1	14
52	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	1.2	13
53	Advantages and Disadvantages of the Amplatzer Vascular Plug IV in Visceral Embolization: Report of 50 Placements. CardioVascular and Interventional Radiology, 2011, 34, 1069-1073.	0.9	12
54	Assessment of fast dynamic imaging and the use of Gdâ€EOBâ€DTPA for MRâ€guided liver interventions. Journal of Magnetic Resonance Imaging, 2011, 34, 874-879.	1.9	12

#	Article	IF	CITATIONS
55	First report on extended distance between tumor lesion and adjacent organs at risk using interventionally applied balloon catheters: a simple procedure to optimize clinical target volume covering effective isodose in interstitial high-dose-rate brachytherapy of liver malignomas. Journal of Contemporary Brachytherapy, 2019, 11, 152-161.	0.4	12
56	Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer, 2015, 15, 517.	1.1	11
57	Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiation Oncology, 2021, 16, 86.	1.2	11
58	Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry. Liver Transplantation, 2021, 27, 928-929.	1.3	11
59	Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. Anticancer Research, 2017, 37, 87-94.	0.5	11
60	Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging, 2022, 22, 1.	1.2	11
61	Needle track seeding in hepatocellular carcinoma after local ablation by high-dose-rate brachytherapy: a retrospective study of 588 catheter placements. Journal of Contemporary Brachytherapy, 2018, 10, 516-521.	0.4	10
62	Biliary duct stenosis after image-guided high-dose-rate interstitial brachytherapy of central and hilar liver tumors. Strahlentherapie Und Onkologie, 2019, 195, 265-273.	1.0	10
63	The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy. Radiation Oncology, 2020, 15, 60.	1.2	10
64	In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy. Radiation Oncology, 2011, 6, 107.	1.2	8
65	Transcatheter arterial embolization of acute bleeding as 24/7 service: predictors of outcome and mortality. British Journal of Radiology, 2018, 91, 20180516.	1.0	8
66	HDR Brachytherapy and SBRT as Bridging Therapy to Liver Transplantation in HCC Patients: A Single-Center Experience. Frontiers in Oncology, 2021, 11, 717792.	1.3	8
67	Reproducibility of CT-Based Hepatocellular Carcinoma Radiomic Features across Different Contrast Imaging Phases: A Proof of Concept on SORAMIC Trial Data. Cancers, 2021, 13, 4638.	1.7	8
68	Combined Transarterial Embolization and Percutaneous Sclerotherapy as Treatment for Refractory and Nonresectable Aneurysmal Bone Cysts. Journal of Vascular and Interventional Radiology, 2021, 32, 1425-1434.e2.	0.2	8
69	Image-Guided Embolotherapy of Arteriovenous Malformations of the Face. CardioVascular and Interventional Radiology, 2022, 45, 992-1000.	0.9	8
70	Retroperitoneoscopic and laparoscopic removal of periadrenally located bronchogenic cysts – aÂsystematic review. Polski Przeglad Chirurgiczny, 2013, 85, 706-13.	0.2	7
71	Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model. Diagnostic and Interventional Radiology, 2016, 22, 378-384.	0.7	7
72	Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy. Anticancer Research, 2019, 39, 2501-2508.	0.5	7

#	Article	IF	CITATIONS
73	Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy. Brachytherapy, 2019, 18, 63-70.	0.2	7
74	Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visceral Medicine, 2020, 36, 506-515.	0.5	7
75	Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization. Cancers, 2021, 13, 1992.	1.7	7
76	Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Research, 2021, 11, 51.	1.1	7
77	Current State of Multidisciplinary Treatment in Cholangiocarcinoma. Digestive Diseases, 2022, 40, 581-595.	0.8	7
78	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and Metabolic Research, 2020, 52, 404-411.	0.7	6
79	Interstitial High-Dose-Rate Brachytherapy of Liver Metastases in Oligometastatic Patients. Cancers, 2021, 13, 6250.	1.7	6
80	Time-Resolved Perfusion Imaging at the Angiography Suite. Investigative Radiology, 2015, 50, 108-113.	3.5	5
81	Molecular imaging and liver function assessment by hepatobiliary MRI. Journal of Hepatology, 2016, 65, 1081-1082.	1.8	5
82	Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection. Digestion, 2018, 98, 69-74.	1.2	5
83	Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. Journal of Contemporary Brachytherapy, 2019, 11, 329-336.	0.4	5
84	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers, 2021, 13, 521.	1.7	5
85	iRESCUE – Interventional embolization of Renal artEries after SurgiCal or traUmatic injury with hEmorrhage. European Journal of Radiology, 2021, 136, 109540.	1.2	5
86	Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. European Radiology, 2022, 32, 1320-1329.	2.3	5
87	The Impact of Unilateral 90Y-radioembolization on Functional Changes in the Contralateral Hepatic Lobe. Annals of Surgery Open, 2021, 2, e095.	0.7	5
88	Improvement of Contrast Media Enhancement in CTA Evaluating Pulmonary Embolism by Utilizing †Delayed' Bolus Tracking in the Descending Aorta. Polski Przeglad Radiologii I Medycyny Nuklearnej, 2016, 81, 422-427.	1.0	4
89	Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. Anticancer Research, 2018, 38, 5401-5407.	0.5	4
90	Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surgery and Nutrition, 2020, 9, 312-321.	0.7	4

#	Article	IF	CITATIONS
91	Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. Anticancer Research, 2020, 40, 4281-4289.	0.5	4
92	Transarterial embolization of acute iatrogenic hemorrhages: predictive factors for mortality and outcome. British Journal of Radiology, 2020, 93, 20190413.	1.0	4
93	Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy – a retrospective observational study. Transplant International, 2021, 34, 465-473.	0.8	4
94	Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma. Digestive Diseases, 2022, 40, 458-467.	0.8	4
95	Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. Frontiers in Oncology, 2021, 11, 667993.	1.3	4
96	Stent-graft placement for hepatic arterial bleeding: assessment of technical efficacy and clinical outcome in a tertiary care center. Hpb, 2022, 24, 672-680.	0.1	4
97	Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdominal Radiology, 2022, 47, 1177-1186.	1.0	4
98	Image-guided interstitial high-dose-rate brachytherapy in the treatment of metastatic esophageal squamous cell carcinoma. Journal of Contemporary Brachytherapy, 2018, 10, 439-445.	0.4	3
99	Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. European Journal of Radiology, 2019, 112, 22-27.	1.2	3
100	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	1.2	3
101	Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinomaâ€"Role of Interventional Radiology. Journal of Clinical Medicine, 2021, 10, 5574.	1.0	3
102	Therapeutic Concepts for Oligometastatic Gastrointestinal Tumours. Visceral Medicine, 2020, 36, 359-363.	0.5	2
103	Multi-modal and sequential treatment of liver cancer and its impact on the gastrointestinal tract. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 48-49, 101709.	1.0	2
104	Lower Ratio of Liver Volume and Body Weight Is a Negative Predictor of Survival after Transjugular Intrahepatic Portosystemic Shunt. Journal of Personalized Medicine, 2021, 11, 903.	1.1	2
105	Artifact reduction of coaxial needles in magnetic resonance imaging-guided abdominal interventions at 1.5 T: a phantom study. Scientific Reports, 2021, 11, 22963.	1.6	2
106	Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2815-2826.	1.2	2
107	Assessment of the tolerance dose of the hepatic reticulo-endothelial system (RES) after single fraction HDR-irradiation: An <i>in-vivo</i> study employing SSPIO. International Journal of Radiation Biology, 2008, 84, 830-837.	1.0	1
108	When Inoperable Becomes Operable?. Journal of Clinical Oncology, 2013, 31, 4474-4474.	0.8	1

#	Article	IF	CITATIONS
109	Angiographic Anatomy and Relevance of 3 and 9 O'clock Arteries During Radioembolization. CardioVascular and Interventional Radiology, 2018, 41, 890-897.	0.9	1
110	Liver Function Changes After Technetium-99m-Macroaggregated Albumin Administration and Their Predictive Value Regarding Hepatotoxicity in Patients Undergoing Yttrium-90-Radioembolization. Anticancer Research, 2021, 41, 437-444.	0.5	1
111	Validation of the collapsed cone algorithm for HDR liver brachytherapy against Monte Carlo simulations. Brachytherapy, 2021, 20, 936-947.	0.2	1
112	Bi-Centric Independent Validation of Outcome Prediction after Radioembolization of Primary and Secondary Liver Cancer. Journal of Clinical Medicine, 2021, 10, 3668.	1.0	1
113	Semi-Automatic MRI Feature Assessment in Small- and Medium-Volume Benign Prostatic Hyperplasia after Prostatic Artery Embolization. Diagnostics, 2022, 12, 585.	1.3	1
114	Minimal invasive Onkologie in der Therapie von Lebermetastasen. Chirurgische Gastroenterologie Interdisziplinar, 2008, 24, 207-215.	0.0	0
115	Reply to: "Toxicity and dosimetry in SORAMIC study― Journal of Hepatology, 2020, 73, 735-736.	1.8	0
116	Posterior Reversible Encephalopathy Syndrome After 90Y-Resin Microspheres Radioembolization. Clinical Nuclear Medicine, 2020, 45, 202-203.	0.7	0
117	Ablation of Liver Metastases byÂBrachytherapy. , 2021, , 105-115.		O
118	Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort. Current Oncology, 2022, 29, 565-577.	0.9	0
119	Reply. Liver Transplantation, 2022, 28, 897-898.	1.3	0
120	Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: The DEMAND randomized phase II clinical trial Journal of Clinical Oncology, 2022, 40, TPS492-TPS492.	0.8	0
121	Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial. Biomedicines, 2022, 10, 1156.	1.4	0
122	Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC $\hat{a} \in A$ Substudy From the SORAMIC Trial., 0, 1, .		O